Posology for Regenerative Therapy

Circ Res. 2017 Nov 10;121(11):1213-1215. doi: 10.1161/CIRCRESAHA.117.312074.

Authors

Andre Terzic¹, Atta Behfar²

Affiliations

¹ From the Department of Cardiovascular Medicine and Department of Molecular Pharmacology and Experimental Therapeutics, Center for Regenerative Medicine, Mayo Clinic, Rochester, MN. terzic.andre@mayo.edu.
² From the Department of Cardiovascular Medicine and Department of Molecular Pharmacology and Experimental Therapeutics, Center for Regenerative Medicine, Mayo Clinic, Rochester, MN.

No abstract available

Keywords: Editorials; biologics; clinical trial; heart failure; pharmacology; regenerative medicine; stem cells.

Publication types

Editorial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Cardiomyopathies*
Humans
Mesenchymal Stem Cells*
Myocardial Ischemia*
Regenerative Medicine

Grants and funding

R01 HL083439/HL/NHLBI NIH HHS/United States